Zoungas S, Patel A, Chalmers J, et al. ADVANCE Collaborative Group. Severe hypoglycaemia and risks of vascular events and death. N Engl J Med 2010; 363: 1410-8.
Nathan DM, Buse JB, Davidson MB, et al. American Diabetes Association. Medical management of hyperglycaemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009; 32: 193-203.
Weng J, Li Y, Xu W, Shi L, Zhang Q, Zhu D, et al. Effect of intensive insulin therapy on beta-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes: A multicentre randomised parallel-group trial. Lancet 2008; 371: 1753-60.
Pharmacologic Approaches to Glycaemic Treatment. American Diabetes Association SO Diabetes Care 2017; 40(Suppl. 1): S64-74.
Wasko MC, Hubert HB, Lingala VB, et al. Hydroxychloroquine and risk of diabetes in patients with rheumatoid arthritis. JAMA 2007; 298: 187-93.
Emami J, Pasutto F, Mercer JR, Jamali F. Inhibition of insulin metabolism by hydroxychloroquine and its enantiomers in cytosolic fraction of liver homogenates from healthy and diabetic rats. Life Sci 1999; 64: 325-35.
Mercer E, Rekedal L, Garg R, et al. Hydroxychloroquine improves insulin sensitivity in obese non-diabetic individuals. Arthritis Res Ther 2012; 14: R135.
Wasko MCM, Hubert HB, Lingala VB, et al. Hydroxychloroquine and risk of diabetes in patients with rheumatoid arthritis. JAMA 2007; 298(2): 187-93.
Solomon DH, Massarotti E, Garg R, et al. Association between disease modifying anti-rheumatic drugs and diabetes risk in patients with rheumatoid arthritis and psoriasis. JAMA 2011; 305(24): 2525-31.
Bili A, Sartorius JA, Kirchner HL, et al. Hydroxychloroquine use and decreased risk of diabetes in rheumatoid arthritis patients. J Clin Rheumatol 2011; 17: 115-20.
Chen YM, Lin CH, Lan TH, et al. Hydroxychloroquine reduces risk of incident diabetes mellitus in lupus patients in a dose dependent manner: a population-based cohort study. Rheumatology (Oxford) 2015.Jan 12. pii keu451 [Epub ahead of print].
Quatraro A, Consoli G, Magno M, et al. Hydroxychloroquine in decompensated, treatment-refractory noninsulin-dependent diabetes mellitus. Annals of Internal Med 1990; 112: 678-81.
Gerstein H, Thorpe K, Taylor D, et al. The effectiveness of hydroxychloroquine in patients with type 2 diabetes mellitus who are refractory to sulfonylureas - a randomized trial. Diabetes Res Clin Pract 2002; 55: 209-19.
Rekedal LR, Massarotti E, Garg R, et al. Changes in Glycated Hemoglobin after Initiation of Hydroxychloroquine or Methotrexate in Diabetic Patients with Rheumatologic Diseases. Arthritis Rheum 2010; 62(12): 3569-73.
Pareek A, Chandurkar N, Thomas N, et al. Efficacy and safety of hydroxychloroquine in the treatment of type 2 diabetes mellitus: a double blind, randomized comparison with pioglitazone. Curr Med Res Opin 2014; 30(7): 1257-66.
Chen L, Magliano DJ, Zimmet PZ. The worldwide epidemiology of type 2 diabetes mellitus – present and future perspectives. Nat Rev Endocrinol 2012; 8: 228-36.
UK Prospective Diabetes Study (UKPDS) Group. Intensive blood glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-53.
UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352: 854-65.
Surendra PS. Comparative study to evaluate effect of hydroxychloroquine versus sitagliptin as add on therapy in patients with type 2 diabetes inadequately controlled on combination with metformin and gliclazide: a multicentre, observational trial. Sch J App Med Sci 2018; 6(5): 2150-6.
Baidya A, Chakravarti HN, Saraogi RK, et al. Efficacy of maximum and optimum doses of hydroxychloroquine added to patients with poorly controlled type 2 diabetes on stable insulin therapy along with glimepiride and metformin: association of high sensitive c-reactive protein (Hs-CRP) and glycosylated haemoglobin (HbA1c). Endocrinol Metab Syndr 20118; 7: 283.
Kumar V, Singh MP, Singh AP, Pandey MS, Kumar S, Kumar S. Efficacy and safety of hydroxychloroquine when added to stable insulin therapy in combination with metformin and glimepiride in patients with type 2 diabetes compare to sitagliptin. Int J Basic Clin Pharmacol 2018; 7: 1959-64.
Larkin ME, Capasso VA, Chen CL, et al. Measuring psychological insulin resistance: Barriers to insulin use. Diabetes Educ 2008; 34(3): 511-7.
Peyrot M, Rubin RR, Lauritzen T, et al. Resis tance to insulin therapy among patients and providers results of the cross-national diabetes attitudes, wishes, and needs (DAWN) study. Diabetes Care 2005; 28(11): 2673-9.